AI can transform pharma, but success depends on a company’s readiness. PQE’s Thomas Carganico explains why preparation is key.
Artificial intelligence (AI) has become one of the most talked-about innovations in the pharmaceutical industry. Promising to accelerate drug discovery, optimize clinical trials, improve manufacturing processes, and enhance pharmacovigilance, AI has garnered attention for its transformative potential. However, despite the growing buzz, many companies are not yet ready to leverage AI effectively. According to Thomas Carganico, Vice President of Strategy at PQE Group, AI is not a one-size-fits-all solution, it is a powerful tool that requires careful planning and preparation.
As a leader in the life sciences sector, Thomas offers a pragmatic perspective on AI adoption. “AI is an accelerator, not a shortcut,” he asserts. “For it to deliver real value, companies must ensure they have the right infrastructure in place to support it.”
AI as an Accelerator, Not a Shortcut
AI is widely hailed as a game-changer in the pharmaceutical industry, with the potential to reduce time-to-market for new drugs. However, Thomas cautions that this optimism can sometimes result in unrealistic expectations. “Life sciences does not need more hype; it needs responsible, strategic adoption,” he explains. “AI must be built on a foundation of clean data, quality processes, and regulatory alignment.”
AI’s effectiveness depends on its application across the entire product lifecycle, from early research and development (R&D) through clinical trials, manufacturing, and post-market surveillance. However, Thomas stresses that it’s not just about acquiring the right tools, it’s about being prepared to use them correctly. “AI can create value when companies have clean data, quality management systems, and clear processes to support it,” he says. “Without these fundamentals, AI implementation may lead to inefficiencies, data silos, and disappointing outcomes.”
The Importance of Being AI-Ready
At PQE Group, Thomas has helped lead efforts to ensure that companies are prepared for the challenges of AI implementation. Rather than just focusing on the tools themselves, PQE Group helps companies ensure they are “AI-ready.” Thomas explains, “The real game-changer is not the technology itself, but how it is integrated across the entire product lifecycle to improve efficiency while maintaining safety.”
This integrated approach to AI adoption contrasts with the more common tactic of running isolated pilot projects. PQE advocates for end-to-end digital transformation, ensuring that every aspect of the drug lifecycle benefits from AI. By focusing on the broader, more strategic application of AI, PQE aims to maximize its potential and drive long-term change in the industry.
However, Thomas emphasizes that AI is just one part of the equation. To be truly “AI-ready,” companies must address foundational issues such as data integrity, regulatory alignment, and clearly defined goals. Without these elements, AI projects can underperform, no matter how advanced the technology may be.
The PQE Difference: A People-First Approach to Innovation
One of PQE Group’s core strengths is its ability to combine deep industry knowledge with a people-first culture. The company is proud to be a women-owned, Great Place to Work–certified organization and a multi-year recipient of Deloitte’s “Best Managed” award. This strong organizational culture has helped PQE expand its global presence while maintaining a focus on quality, sustainability, and diversity.
Thomas attributes much of PQE’s success to its ability to combine industry expertise with cutting-edge solutions. “What differentiates us is our ability to deliver enterprise-level impact with the agility of an independent global firm. We bridge the gap between European regulatory rigor and U.S. market innovation, creating a truly global presence,” he says. This combination of local expertise and global reach has positioned PQE as a trusted partner to pharmaceutical and biotech companies around the world.
Driving Real Change in the Life Sciences Sector
AI is one of the most exciting developments in the life sciences sector. However, for organizations to fully realize its potential, they must take a careful, measured approach to its implementation. Thomas’ work at PQE Group centers around guiding companies through this process.
He adds, “Our focus is not on jumping on the AI bandwagon, but on ensuring companies have the groundwork in place to leverage AI effectively for long-term, sustainable value.”
PQE Group has worked with companies across the product lifecycle, helping them align digital transformation initiatives with regulatory compliance and business growth. By applying AI strategically, PQE ensures that its clients can achieve meaningful, measurable results.
Looking Ahead: The Future of AI in Life Sciences
As the pharmaceutical industry continues to evolve digitally, AI’s role will only grow. But Thomas’ perspective serves as a reminder that adopting AI should be a carefully considered, data-driven decision. Companies must ensure they are ready for it, not just in terms of technology but also organizational structure.
“The key to success is readiness,” Thomas says. “AI works best when it’s applied in an environment that’s well-prepared to support it.” By focusing on data integrity, regulatory alignment, and process improvement, PQE Group helps life sciences companies set themselves up for lasting success.
PQE’s Services & Reputation
If you’re interested in exploring how PQE Group can assist your organization in its AI journey, visit PQE Group’s website to learn more.
Follow Thomas Carganico’s insights on LinkedIn for further perspectives on AI and digital transformation in life sciences: Thomas Carganico on LinkedIn
